Tardive dyskinesia syndromes: Current concepts

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Aquino, Camila Catherine H ^a   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Antipsychotics; Tardive dyskinesia; Tardive syndrome

Indexed keywords

AMANTADINE; ATYPICAL ANTIPSYCHOTIC AGENT; BACLOFEN; BOTULINUM TOXIN; CLONAZEPAM; HERBACEOUS AGENT; PROPRANOLOL; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; TETRABENAZINE; TRIHEXYPHENIDYL;

AKATHISIA; ARTICLE; BLEPHAROSPASM; BRAIN DEPTH STIMULATION; CERVICAL DYSTONIA; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; GENETIC ASSOCIATION; GILLES DE LA TOURETTE SYNDROME; GINKGO BILOBA; HUMAN; INVASIVE PROCEDURE; LOW DRUG DOSE; MYOCLONUS; NEUROPATHOLOGY; NONHUMAN; OROMANDIBULAR DYSTONIA; PATHOPHYSIOLOGY; PHENOMENOLOGY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RISK FACTOR; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREMOR;

ANTIPSYCHOTICS; TARDIVE DYSKINESIA; TARDIVE SYNDROME;

HUMANS; MOVEMENT DISORDERS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; RISK FACTORS;

EID: 84887929277     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70028-2     Document Type: Article

References (30)

1. Bhidayasiri R, Boonyawairoj S Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011, 87:132-141.
2. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. 4th ed., Text Revision (DSM-IV-TR).
3. Ortí-Pareja M, Jiménez-Jiménez FJ, Vázquez A, Catalán MJ, Zurdo M, Burguera JA, et al. Drug-induced tardive syndromes. Parkinsonism Relat Disord 1999, 5:59-65.
4. Correll CU, Schenk EM Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21:151-156.
5. 123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006, 21:510-514.
6. Foubert-Samier A, Helmer C, Perez F, Le Goff M, Auriacombe S, Elbaz A, et al. Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort. Neurology 2012, 79:1615-1621.
7. Tarsy D, Baldessarini RJ Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?. Mov Disord 2006, 21:589-598.
8. Tenback DE, van Harten PN, van Os J Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: A meta-analysis. Mov Disord 2009, 24:2309-2315.
9. Meltzer HY Update on typical and atypical antipsychotic drugs. Annu Rev Med 2013, 64:393-406.
10. Correll CU, Leucht S, Kane JM Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004, 161:414-425.
11. Loonen AJM, Ivanova SA New insights into the mechanism of drug-induced dyskinesia. CNS Spectr 2012, 18:15-20.
12. Turrone P, Remington G, Kapur S, Nobrega JN The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003, 165:166-171.
13. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000, 152:174-180.
14. Teo JT, Edwards MJ, Bhatia K Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis. Mov Disord 2012, 27:1205-1215.
15. Lohr JB, Kuczenski R, Niculescu AB Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17:47-62.
16. Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23:170-177.
17. Ferentinos P, Dikeos D Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry 2012, 25:381-390.
18. Zhang XY, Zhang W-F, Zhou D-F, Chen DC, Xiu MH, Wu H-R, et al. Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012, 72:700-706.
19. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
20. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia - Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006, 63:1079-1087.
21. Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009, 166:1055-1062.
22. Fasano A, Bentivoglio AR Tetrabenazine. Expert Opin Pharmacother 2009, 10:2883-2896.
23. Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA Evidence-based guideline: Treatment of tardive syndromes: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013, 81:463-469.
24. LeWitt PA Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol 2013, 36:92-93.
25. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S Effects of amantadine on tardive dyskinesia. Clin Neuropharmacol 2010, 33:271-275.
26. Factor SA Propranolol therapy for tardive dyskinesia revisited. Mov Disord 2012, 27:1703.
27. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela B-A, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007, 68:1648-1654.
28. Zhang W-F, Tan Y-L, Zhang XY, Chan RCK, Wu H-R, Zhou D-F Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:615-621.
29. Pedroso JL, Henriques Aquino CC, Escórcio Bezerra ML, Baiense RF, Suarez MM, Dutra LA, et al. Ginkgo biloba and cerebral bleeding. Neurologist 2011, 17:89-90.
30. Mentzel CL, Tenback DE, Tijssen MAJ, Visser-Vandewalle VERM, van Harten PN Efficacy and safety of deep brain stimulation in patients with medication-induced tardive dyskinesia and/or dystonia. J Clin Psychiatry 2012, 73:1434-1438.